GSK3B and Hepatic fibrosis: In summary, live-cell imaging of human microHOs has identified GSK3β and p38 MAPK inhibitors as potential new therapies for liver fibrosis, and it is likely that other new therapies and their mechanism(s) of action could subsequently be identified using this system.